

September 1, 2025

The Manager – Listing  
**BSE Limited**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Disclosure of ESG Rating**

We wish to inform you that Crisil ESG Ratings & Analytics Limited (Crisil ESG Ratings) has, vide its Environmental, Social, and Governance (ESG) Report as received by AstraZeneca Pharma India Limited ('the Company') on August 29, 2025, assigned an ESG rating of 58 based on publicly available information pertaining to fiscal period 2025.

Please note that the Company has not engaged Crisil ESG Ratings. They have independently prepared the report based on publicly available information.

This intimation is in compliance with Regulation 30 of SEBI Listing Regulations read with the SEBI Circular SEBI/HO/CFD/CFD-PoD- 1/P/CIR/2023/123 dated July 13, 2023.

Further, the aforementioned report was accessed today i.e., September 1, 2025, and some time was spent in good faith for evaluation of the contents and conditions laid in the report.

Kindly take the above information on record.

Thanking you,

For AstraZeneca Pharma India Limited

**Manasa. R**  
Company Secretary